Carmelo  Grasso

Carmelo Grasso

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2014 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
YOYohei Ohno
Yohei Ohno
GAGuilherme F. Attizzani
Guilherme F. Attizzani
DCDavide Capodanno
Davide Capodanno
SCStefano Cannata
Stefano Cannata
FDFabio Dipasqua
Fabio Dipasqua
CGCarmelo Grasso
Carmelo Grasso
The aim of this study was to evaluate the association of baseline tricuspid regurgitation (TR) on the outcomes after percutaneous mitral valve repair (PMVR) with the MitraClip system. Data from 146 consecutive patients with functional mitral regurgitation (MR) were obtained. Two different groups, dichotomized according to the degree of pre-procedural TR (moderate/severe, n = 47 and none/mild, n = 99), had their clinical and echocardiographic outcomes through 12-month compared. At 30-day, the primary safety endpoint was significantly higher in moderate/severe TR compared with none/mild TR (10.6 vs. 2.0%, P = 0.035). Marked reduction in MR grades observed post-procedure were maintained through 12 months. Although NYHA functional class significantly improved in both groups compared with baseline, it was impaired in moderate/severe TR compared with the none/mild TR group (NYHA > II at 30 day: 33.3 vs. 9.2%, P < 0.001; at 1 year: 38.5 vs. 12.3%, respectively, P = 0.006). Left ventricle reverse remodelling and ejection fraction improvement were revealed in both groups. The primary efficacy endpoint at 12-month determined by freedom from death, surgery for mitral valve dysfunction, or grade ≥3+ MR was comparable between groups, but combined death and re-hospitalization for heart failure rates were higher in the moderate/severe TR group. Multivariable Cox regression analysis demonstrated that baseline moderate/severe TR and chronic kidney disease were independent predictors of this combined endpoint. Although PMVR with MitraClip led to improvement in MR, TR, and NYHA functional class in patients with baseline moderate/severe TR, the primary safety endpoint at 30-day was impaired, while moderate/severe TR independently predicted death and re-hospitalization for heart failure at 12-month.

1 January 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
GAGuilherme F. Attizzani
Guilherme F. Attizzani
YOYohei Ohno
Yohei Ohno
DCDavide Capodanno
Davide Capodanno
SCStefano Cannata
Stefano Cannata
FDFabio Dipasqua
Fabio Dipasqua
CGCarmelo Grasso
Carmelo Grasso

1 March 2014 in JACC
Verified
Journal Article
Closed access
CGCarmelo Grasso
Carmelo Grasso
YOYohei Ohno
Yohei Ohno
GAGuilherme F. Attizzani
Guilherme F. Attizzani
SCStefano Cannata
Stefano Cannata
SISebastiano Immè
Sebastiano Immè
CTCorrado Tamburino
Corrado Tamburino

16 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMagnus Hagnäs
Magnus Hagnäs
CGCarmelo Grasso
Carmelo Grasso
MSMaria Elena Di Salvo
Maria Elena Di Salvo
ACAnna Caggegi
Anna Caggegi
MBMarco Barbanti
Marco Barbanti
CTCorrado Tamburino
Corrado Tamburino
Objectives: To investigate how the changes of left ventricle ejection fraction (LVEF) between admission and discharge affected the long-term outcome in patients who underwent percutaneous edge-to-edge mitral valve repair for secondary mitral regurgitation. Background: An acute impairment of LVEF after surgical repair of mitral regurgitation, known as afterload mismatch, has been associated with increased all-cause mortality. Afterload mismatch after percutaneous edge-to-edge mitral valve repair has been postulated to be a transient phenomenon. Methods: This study is based on a single-center, retrospective, observational registry of patients who underwent percutaneous edge-to-edge mitral valve repair with the MitraClip (Abbot Vascular) system for the treatment of symptomatic, moderate-to-severe mitral regurgitation. We included data on 399 patients who underwent percutaneous edge-to-edge mitral valve repair for secondary mitral regurgitation. Expert echocardiographers assessed LVEF before the procedure and at discharge. The patients were divided into three groups according to the difference of periprocedural LVEF measurements: unchanged (n = 318), improved (n = 40), and decreased (n = 41) LVEF. Results: The median follow-up time was 2.0 years. When adjusted for gender, NYHA class and estimated glomerular filtration rate, decreased postprocedural LVEF was associated with an increased risk of death (adjusted HR 2.05, 95% CI 1.26–3.34) and increased postprocedural LVEF with a reduced risk of death (adjusted HR 0.47, 95% CI 0.24–0.91) compared to unchanged LVEF. Conclusion: Among patients who underwent percutaneous edge-to-edge mitral valve repair, decreased postprocedural LVEF was associated with increased mortality, while improved LVEF was associated with lower mortality compared to unchanged LVEF.

1 December 2017 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
CGCarmelo Grasso
Carmelo Grasso
ARAntonio Popolo Rubbio
Antonio Popolo Rubbio
The PASCAL transcatheter mitral valve repair system for the treatment of mitral regurgitation: another piece to the puzzle of edge-to-edge technique

31 December 2014 in Circulation Journal
Verified
Journal Article
Closed access
PDF file
CGCarmelo Grasso
Carmelo Grasso
DCDavide Capodanno
Davide Capodanno
CTCorrado Tamburino
Corrado Tamburino
YOYohei Ohno
Yohei Ohno
Transcatheter mitral valve intervention has emerged as an effective treatment option for symptomatic severe mitral regurgitation in patients considered to be inoperable or at high operative risk for surgical mitral valve surgery. Most transcatheter approaches are modifications of existing surgical approaches. Transcatheter edge-to-edge mitral valve repair with the MitraClip system has the largest clinical experience to date, as it offers a sustained clinical benefit in selected patients. This review aims to provide an up-to-date overview of transcatheter mitral valve interventions, including leaflet repair, annuloplasty, and mitral valve implantation. (Circ J 2015; 79: 1164–1171)